Härtter S - Search Results

1

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Härtter S, et al. Ther Drug Monit. 1998 Aug;20(4):446-9. doi: 10.1097/00007691-199808000-00016. Ther Drug Monit. 1998. PMID: 9712472

2

Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum.

Shams M, Hiemke C, Härtter S. Shams M, et al. Among authors: hartter s. Ther Drug Monit. 2004 Feb;26(1):78-84. doi: 10.1097/00007691-200402000-00015. Ther Drug Monit. 2004. PMID: 14749554

3

Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography.

Härtter S, Wetzel H, Hiemke C. Härtter S, et al. Clin Chem. 1992 Oct;38(10):2082-6. Clin Chem. 1992. PMID: 1394994

4

Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients.

Härtter S, Wetzel H, Hammes E, Hiemke C. Härtter S, et al. Psychopharmacology (Berl). 1993;110(3):302-8. doi: 10.1007/BF02251285. Psychopharmacology (Berl). 1993. PMID: 7831423 Clinical Trial.

5

Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography.

Härtter S, Hermes B, Szegedi A, Hiemke C. Härtter S, et al. Ther Drug Monit. 1994 Aug;16(4):400-6. doi: 10.1097/00007691-199408000-00011. Ther Drug Monit. 1994. PMID: 7974631

6

Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.

Szegedi A, Wetzel H, Leal M, Härtter S, Hiemke C. Szegedi A, et al. Among authors: hartter s. J Clin Psychiatry. 1996 Jun;57(6):257-64. J Clin Psychiatry. 1996. PMID: 8666564 Clinical Trial.

7

Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.

Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Härtter S, et al. Pharmacopsychiatry. 1998 Sep;31(5):199-200. doi: 10.1055/s-2007-979327. Pharmacopsychiatry. 1998. PMID: 9832352 Clinical Trial.

8

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.

Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Härtter S, Hiemke C, Wetzel H. Szegedi A, et al. Among authors: hartter s. Pharmacopsychiatry. 1999 Jul;32(4):148-53. doi: 10.1055/s-2007-979221. Pharmacopsychiatry. 1999. PMID: 10505485 Clinical Trial.

9

Pharmacokinetics of selective serotonin reuptake inhibitors.

Hiemke C, Härtter S. Hiemke C, et al. Among authors: hartter s. Pharmacol Ther. 2000 Jan;85(1):11-28. doi: 10.1016/s0163-7258(99)00048-0. Pharmacol Ther. 2000. PMID: 10674711 Review.

10

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.

Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Weigmann H, et al. Among authors: hartter s. Ther Drug Monit. 2001 Aug;23(4):410-3. doi: 10.1097/00007691-200108000-00015. Ther Drug Monit. 2001. PMID: 11477325

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters